Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics

Radium-223-dichloride ((223)RaCl(2)) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive doses of (223)RaCl(2) at 4 week...

Descripción completa

Detalles Bibliográficos
Autores principales: Kairemo, Kalevi, Joensuu, Timo, Rasulova, Nigora, Kiljunen, Timo, Kangasmäki, Aki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665607/
https://www.ncbi.nlm.nih.gov/pubmed/26854158
http://dx.doi.org/10.3390/diagnostics5030358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665607/
https://www.ncbi.nlm.nih.gov/pubmed/26854158
http://dx.doi.org/10.3390/diagnostics5030358

Ejemplares similares